The article discusses the innovations in insulin degludec U-100 and U-200 formulations. These include the modification of the insulin structure at the B30 position to allow the conformation of a di-hexamer, the duration of the glucose-lowering effect of the degludec, and the similar pharmacodynamic profiles of both insulin formulations at steady-state.